Chemotherapy regimens in early breast cancer: Major controversies and future outlook

Expert Review of Anticancer Therapy

Volumn 13, Issue 2, 2013, Pages 165-178

  Joerger, Markus ^a   Thürlimann, Beat ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

adjuvant chemotherapy; anthracyclines; breast cancer; estrogen receptor; gene expression signatures; HER2; taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UROKINASE;

ADJUVANT THERAPY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYNEUROPATHY; PROTEIN EXPRESSION; REVIEW; TOPOISOMERASE 2A GENE; TUMOR SUPPRESSOR GENE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAXOIDS; TRANSCRIPTOME;

EID: 84873890597     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.172     Document Type: Review

References (95)

1. Peto R, Davies C, Godwin J et al. Comparisons between different polychem-otherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 379(9814), 432-444 (2012).
2. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26(1), 44-53 (2008).
3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8), 1736-1747 (2011)
4. National Comprehensive Cancer Network Practice Guidelines in Oncology-v.1.2012. (2012).
5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21(17), 3357-3365 (2003).
6. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
7. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: frst report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21(8), 1431-1439 (2003).
8. Martin M, Pienkowski T, Mackey J et al.; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352(22), 2302-2313 (2005).
9. Roché H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J. Clin. Oncol. 24(36), 5664-5671 (2006).
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
11. Albain KS, Barlow WE, Ravdin PM et al.; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a Phase 3, open-label, randomised controlled trial. Lancet 374(9707), 2055-2063 (2009).
12. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin- cyclophospha-mide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fuorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 8 (9), 1483-1496 (1990).
13. Hutchins LF, Green SJ, Ravdin PM et al. Randomized, controlled trial of cyclophos-phamide, methotrexate, and fuorouracil versus cyclophosphamide, doxorubicin, and fuorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J. Clin. Oncol. 23(33), 8313-8321 (2005).
14. Levine MN, Bramwell V, Pritchard K et al. A pilot study of intensive cyclophospha-mide, epirubicin and fuorouracil in patients with axillary node positive or locally advanced breast cancer. Eur. J. Cancer 29A(1), 37-43 (1992).
15. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fuorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fuorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16(8), 2651-2658 (1998).
16. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fuorouracil with cyclophosphamide, methotrexate, and fuorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J. Clin. Oncol. 23(22), 5166-5170 (2005).
17. Martin M, Villar A, Sole-Calvo A et al.; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Doxorubicin in combination with fuorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fuorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann. Oncol. 14(6), 833-842 (2003).
18. Bonneterre J, Roché H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 23(12), 2686-2693 (2005).
19. Trudeau M, Charbonneau F, Gelmon K et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 6(11), 886-898 (2005).
20. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst. 90(16), 1205-1211 (1998).
21. Fisher B, Anderson S, Wickerham DL et al. Increased intensifcation and total dose of cyclophosphamide in a doxorubicin-cyclo-phosphamide regimen for the treatment of primary breast cancer: fndings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol. 15 (5), 1858-1869 (1997).
22. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21(6), 976-983 (2003).
23. Piccart MJ, Di Leo A, Beauduin M et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophospha-mide with cyclophosphamide, methotrex-ate, and fuorouracil in node-positive breast cancer. J. Clin. Oncol. 19 (12), 3103-3110 (2001).
24. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330(18), 1260-1266 (1994).
25. Del Mastro L, Bruzzi P, Nicolò G et al. HER2 expression and effcacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br. J. Cancer 93(1), 7-14 (2005).
26. Hayes DF, Thor AD, Dressler LG et al.; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357 (15), 1496-1506 (2007).
27. Gennari A, Sormani MP, Pronzato P et al. HER2 status and effcacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl Cancer Inst. 100(1), 14-20 (2008).
28. Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res. Treat. 109(2), 209-229 (2008).
29. Järvinen TA, Liu ET. Simultaneous amplifcation of HER-2 (ERBB2) and topoisomerase IIα (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr. Cancer Drug Targets 6(7), 579-602 (2006).
30. O'Malley FP, Chia S, Tu D et al. Topoi-somerase II α protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res. Treat. 128(2), 401-409 (2011).
31. Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-α gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 29(7), 859-867 (2011).
32. Olsen KE, Knudsen H, Rasmussen BB et al.; Danish Breast Cancer Co-operative Group. Amplifcation of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 43(1), 35-42 (2004).
33. Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J. Characterization of topoisomer-ase II α gene amplifcation and deletion in breast cancer. Genes. Chromosomes Cancer 26(2), 142-150 (1999).
34. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplifcation and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracy-cline-based therapy or with cyclophospha-mide, methotrexate, and 5-fuorouracil. Clin. Cancer Res. 8 (5), 1107-1116 (2002).
35. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN. Role of anthracyclines in the treatment of early breast cancer. J. Clin. Oncol. 27(28), 4798-4808 (2009).
36. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: fndings from National Surgical Adjuvant Breast and Bowel Project B-23. J. Clin. Oncol. 19(4), 931-942 (2001).
37. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemothera py for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 23(16), 3686-3696 (2005).
38. Kataja V, Castiglione M; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 10-14 (2009).
39. Foon KA, Lutzky J, Baral RN et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 18(2), 376-384 (2000).
40. Martín M, Rodríguez-Lescure A, Ruiz A et al.; GEICAM 9906 Study Investigators. Randomized Phase 3 trial of fuorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J. Natl Cancer Inst. 100(11), 805-814 (2008).
41. Burnell M, Levine MN, Chapman JA et al. Cyclophosphamide, epirubicin, and fuorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J. Clin. Oncol. 28(1), 77-82 (2010).
42. Polyzos A, Malamos N, Boukovinas I et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res. Treat. 119(1), 95-104 (2010).
43. Francis P, Crown J, Di Leo A et al.; BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J. Natl Cancer Inst. 100 (2), 121-133 (2008).
44. Goldstein LJ, O'Neill A, Sparano JA et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J. Clin. Oncol. 26(25), 4092-4099 (2008).
45. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival beneft compared with doxorubicin and cyclophos-phamide: 7-year follow-up of US Oncology Research Trial 9735. J. Clin. Oncol. 27(8), 1177-1183 (2009).
46. Qin Y Y, Li H, Guo XJ et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS ONE 6(11), e26946 (2011).
47. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358(16), 1663-1671 (2008).
48. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chemother. Rep. 35, 1-111 (1964).
49. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 333 (22), 1456-1461 (1995).
50. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70(1) 163-169 (1986).
51. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 48(24 Pt 1) 7067-7071 (1988).
52. Venturini M, Del Mastro L, Aitini E et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J. Natl Cancer Inst. 97(23), 1724-1733 (2005).
53. Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO Phase III study. J. Clin. Oncol. 28(17), 2874-2880 (2010).
54. Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al.; EORTC. Final results of a randomized Phase III trial comparing cyclophosphamide, epirubicin, and fuorouracil with a dose-intensifed epirubicin and cyclophosphamide + flgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 21(5), 843-850 (2003).
55. Kümmel S, Krocker J, Kohls A et al. Randomised trial: survival beneft and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br. J. Cancer 94(9), 1237-1244 (2006).
56. Lemos Duarte I, da Silveira Nogueira Lima JP, Passos Lima CS, Deeke Sasse A. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast 21(3), 343-349 (2012).
57. Baldini E, Gardin G, Giannessi PG et al. Accelerated versus standard cyclophospha-mide, epirubicin and 5-fuorouracil or cyclophosphamide, methotrexate and 5-fuorouracil: a randomized Phase III trial in locally advanced breast cancer. Ann. Oncol. 14(2), 227-232 (2003).
58. Jones RL, Walsh G, Ashley S et al. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegflgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br. J. Cancer 100(2), 305-310 (2009).
59. Loi S, Piccart M, Sotiriou C. The use of gene-expression profling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit. Rev. Oncol. Hematol. 61(3), 187-194 (2007).
60. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
61. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classifcation of estrogen receptor-positive/luminal breast cancers. Adv. Anat. Pathol. 19(1), 39-53 (2012).
62. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101(10), 736-750 (2009).
63. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361(8), 766-776 (2009).
64. Howell A, Cuzick J, Baum M et al.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
65. Pagani O, Gelber S, Simoncini E et al.; International Breast Cancer Study Group. Is adjuvant chemotherapy of beneft for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res. Treat. 116(3), 491-500 (2009).
66. Regan MM, Pagani O, Walley B et al.; SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann. Oncol. 19 (7), 1231-1241 (2008).
67. Thürlimann B, Price KN, Gelber RD et al. Is chemotherapy necessary for premeno-pausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res. Treat. 113(1), 137-144 (2009).
68. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 4(4), 459-471 (1986).
69. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol. 8(6), 1005-1018 (1990).
70. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 89(22), 1673-1682 (1997).
71. International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmeno-pausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst. 94(14), 1054-1065 (2002).
72. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14), 1658-1667 (2006).
73. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24(7), 1037-1044 (2006).
74. Mazouni C, Kau SW, Frye D et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann. Oncol. 18(5), 874-880 (2007).
75. Colleoni M, Bagnardi V, Rotmensz N et al. Increasing steroid hormone receptors expression defnes breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res. Treat. 116 (2), 359-369 (2009).
76. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
77. Filipits M, Rudas M, Jakesz R et al.; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17(18), 6012-6020 (2011).
78. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12(6), 631-635 (2007).
79. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
80. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
81. Paik S, Tang G, Shak S et al. Gene expression and beneft of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
82. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profles in breast cancer: toward a unifed understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(4), R65 (2008).
83. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24(19), 2200-2208 (2008).
84. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 415(6871) 530-536 (2002).
85. van de Vijver M. Gene-expression profling and the future of adjuvant therapy. Oncologist, 10(Suppl. 2), 30-34 (2005).
86. Buyse M, Loi S, van't Veer L et al.; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98 (17), 1183-1192 (2006).
87. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profle: the MINDACT trial. J. Clin. Oncol. 26(5), 729-735 (2008).
88. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37(7), 541-548 (2004).
89. Harbeck N, Kates RE, Schmitt M et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer 5(5), 348-352 (2004).
90. Sweep CG, Geurts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer 78(11), 1434-1441 (1998).
91. Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst. 94(2), 116-128 (2002).
92. Harris L, Fritsche H, Mennel R et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287-5312 (2007).
93. Kreienberg R, Kopp I, Albert U, Bartsch HH. Interdisziplinäre S3-Leitlinie für die Diagnostik. Therapie und Nachsorge des Mammakarzinoms (2008).
94. Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30(15), 1879-1887 (2012).
95. Pritchard KI, Paterson AH, Fine S et al. Randomized trial of cyclophosphamide, methotrexate, and fuorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J. Clin. Oncol. 15(6), 2302-2311 (1997).